USA

The U.S. FDA granted accelerated approval for Iqirvo as a first-in-class PPAR treatment for primary biliary cholangitis. Iqirvo is the first new medicine approved in nearly a decade for this rare liver...

The FDA Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that donanemab shows clinical benefit for the treatment of early Alzheimer's disease. - If approved, donanemab would become the second disease-modifying drug for Alzheimer's to receive full approval, expanding the arsenal of available drugs needed to treat Alzheimer's with combination therapy.

Considering both efficacy and side effects, Ubrogepant is effective for immediate symptom management with known, manageable side effects at recommended doses. Atogepant would appeal to those requiring prophylactic treatment, with efficacy and side effects assessed over longer-term usage. Given these points, choosing between the two should be tailored to the treatment intent (acute vs. preventive) and the patient’s health profile.